Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALIVIALUX is an ophthalmic combination drug developed and marketed by Denver Farma. It is indicated for the temporary relief of symptoms associated with allergic conjunctivitis, such as ocular redness, itching, and congestion. The formulation consists of naphazoline hydrochloride, a sympathomimetic agent that acts as an alpha-adrenergic agonist to induce vasoconstriction of the conjunctival blood vessels, and pheniramine maleate, a first-generation antihistamine that competitively inhibits H1 receptors to reduce allergic inflammation and pruritus. The product is typically administered topically as eye drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline + pheniramine (Denver Farma).